Clinical Trials
Proteomics Identifies Diagnostic Models for Leptomeningeal Metastasis in Lung Adenocarcinoma
Ding et alMolecular Diagnosis & Therapy

In an exploratory cohort study evaluating patients with advanced lung adenocarcinoma (LUAD), targeted proteomic profiling using the Olink Target-96 platform was utilized to establish diagnostic models and identify biomarkers for type 1 leptomeningeal metastasis (LM). Blood and cerebrospinal fluid (CSF) samples (174 total specimens: 88 blood and 86 CSF) were prospectively collected from patients with and without LM. Predictive models were developed using logistic regression and subsequently evaluated through internal temporal validation.
The resulting 12-protein CSF-based diagnostic model demonstrated high discriminatory performance, yielding an area under the curve (AUC) of 0.984, with 96.7% sensitivity and 96.7% specificity in the training cohort, and an AUC of 0.944 in the temporal test set. In comparison, a 7-protein plasma-based model achieved an AUC of 0.918 with 100% sensitivity and 73.0% specificity in the training cohort, which decreased to an AUC of 0.765 in the temporal test set.
Differential expression analysis of CSF specimens identified 65 proteins that differed significantly between patients with LM and those without LM, with enrichment analysis indicating predominant clustering in inflammatory and immune activation pathways. Additionally, evaluation of individual candidate markers demonstrated that tumor necrosis factor receptor superfamily member 9 (TNFRSF9) alone yielded an AUC of 0.960 for distinguishing the LM cohort from patients without leptomeningeal or brain metastases.
Key Takeaways
- A 12-protein cerebrospinal fluid diagnostic model achieved an AUC of 0.984 with 96.7% sensitivity and 96.7% specificity in the training set, maintaining an AUC of 0.944 in internal temporal validation.
- A 7-protein plasma diagnostic model achieved an AUC of 0.918 with 100% sensitivity and 73.0% specificity in the training set, and an AUC of 0.765 in the validation set.
- Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) in cerebrospinal fluid achieved an AUC of 0.960 as a standalone biomarker for distinguishing leptomeningeal metastasis from cases without leptomeningeal or brain metastasis.
Read the original sourceMolecular Diagnosis & Therapy
